TMCnet News
PositiveID Corporation Wins Gold at Connected World Value Chain Awards for Its iglucose Mobile Health Solution for Diabetes ManagementDELRAY BEACH, Fla., Jun 19, 2012 (GlobeNewswire via COMTEX) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it has won the Gold award for its iglucose(R) mobile health solution for diabetes management at Connected World magazine's Value Chain Awards in the Home Health category. Held as part of the Connected World Conference, the Value Chain Awards Gala honors success in the M2M (machine-to-machine) and connected devices marketplace. Sierra Wireless was also honored for their role as a technology enabler for iglucose. PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By wirelessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals. This makes it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose is compatible with leading FDA-cleared glucometers and does not require the use of a cell phone or a wireless plan. "The 2012 winners represent successful implementations in home health, education, emergency response, tracking, and even the prevention of distracted driving. This is a great illustration as to how M2M technology and connected devices can be relied upon to not only make our lives more convenient and efficient, but much safer and responsible," says Peggy Smedley, editorial director, Connected World. "Congratulations to all of the individuals and companies honored tonight." William J. Caragol, Chairman and CEO of PositiveID, said, "Winning gold at Connected World's Value Chain Awards is another validation of the mobile health community's belief in the value of iglucose." The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour(R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com. About PositiveID Corporation PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com. The PositiveID Corporation logo is available at //www.globenewswire.com/newsroom/prs/?pkgid=7717 Statements about PositiveID's future expectations, including the likelihood that iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition; the likelihood that iglucose makes it possible to improve care in a cost-effective manner; the likelihood that iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition; the likelihood that family members have greater peace of mind; the likelihood that the Company is continually adding to this list of supported glucose meters; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize its diabetes management products including iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on May 14, 2012, November 14, 2011, and August 15, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. This news release was distributed by GlobeNewswire, www.globenewswire.com SOURCE: PositiveID Corporation (Logo: http://media.primezone.com/cache/12878/int/8492.jpg) CONTACT: PositiveID Corporation Allison Tomek 561-805-8000 [email protected] |
